The US Food and Drug Administration (FDA) has awarded fast track designation to Moderna mRNA vaccine candidate, mRNA-1273, developed to protect against Covid-19.
Fast track designation enables development and speed-up of the review of therapies and vaccines that target serious conditions and fill an unmet medical need.
Programmes with the designation could see early and frequent communication with the FDA, along with a rolling submission of the marketing application.
Previously, Moderna obtained fast track designation for its investigational Zika vaccine, methylmalonic acidemia and propionic acidemia programmes.